ArticleMedicine2025
Associations of 2923 plasma proteins with incident atopic dermatitis in a prospective cohort study and genetic analysis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mendelian randomization studies in atopic dermatitis: causal insights across omics layers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between proteomics and atopic dermatitis (AD) remains underexplored but holds significant potential for therapeutic intervention. We analyzed data from a longitudinal cohort of 51,458 UK Biobank participants to investigate the relationship between AD risk and serum levels of 2923 proteins. Multivariate Cox regression was initially applied to evaluate associations between protein concentrations and AD incidence. Subsequently, two-sample Mendelian randomization (MR), summary-data-based MR, and colocalization analyses were conducted to establish genetic associations with AD. Our analysis identified 23 proteins significantly associated with AD risk. Two-sample MR further validated ten proteins exhibiting robust causal relationships with AD. Comprehensive assessments using summary-data-based MR, colocalization, and differential expression analyses pinpointed 5 key proteins - CACYBP, CETN3, MOCS2, TNFAIP8, and PVALB - with potential protective effects against AD. A novel protein-based scoring system, integrating these biomarkers with inflammatory markers, achieved superior predictive accuracy for AD onset (area under the curve = 0.833), outperforming both the polygenic risk score and eosinophil percentage. This extensive proteomic and genetic study within a European adult cohort provides compelling causal evidence for several proteins as potential biomarkers for AD, offering new avenues for early diagnosis and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.